Antibodies by Design: Accelerating biotherapeutic R&D

Join us on November 4th to discuss the science and experimental evidence behind Scala Biodesign’s antibody design technology.

Scala’s co-founders Ravit Netzer and Adi Goldenzweig will explain how we combine AI and physics-based calculations to improve multiple antibody properties. They’ll walk through experimental case studies, the challenges each project set out to solve, and what the results mean for teams developing therapeutic antibodies.